HC Wainwright cuts Ascendis Pharma target to $344
HC Wainwright & Co. cut its Ascendis Pharma price target to $344.00/share from $345.00.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.